A Phase (Ph) 1b/2 Study Of Tak-659, An Investigational Dual Flt-3 And Syk Inhibitor, In Patients (Pts) With Relapsed Or Refractory Acute Myelogenous Leukemia (R/R Aml)
BLOOD(2017)
摘要
Background
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要